Clinical trials: Liver Inflammation
Vaccine Reaction, Vaccine Adverse Reaction
Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)
This is a phase 3, experimental, randomized, observer-blind, lot to lot consistency study. The primary objective of this study is to assess the protectivity of In-House Recombinant Hepatitis B vaccine 28 days after 3 doses…
- Trial name
- NCT05482295
- Testing
- In-House Recombinant Hepatitis B (Bio Farma) vaccine, Registered Hepatitis B vaccine recombinant (Engerix-B)
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Active or Ex-injection Drug Users, Indication of Hepatitis C Screening
Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care
Rapid tests are increasingly used in medical practice, notably to screen for HIV. Their use has been associated with a faster linkage to care and lower rates of loss to follow up.
- Trial name
- NCT02084719
- Testing
- Oraquick HCV Rapid Antibody Test, Standard algorithm
- Where
- Canada
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis, Fatigue in Workers With Chronic C Hepatitis
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.
- Conditions
- Work Productivity and Activity Impairment in Workers With Chronic C Hepatitis, Fatigue in Workers With Chronic C Hepatitis, Fatigue
- Trial name
- NCT01913964
- Testing
- Acetylcarnitine
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Catania
Hepatitis B Infection, Pregnant Women
TAF in Early/Middle Pregnancy With CHB
The goal of this clinical trial is to study the efficacy and safety of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate(TDF) in early and middle pregnancy with chronic hepatitis B.
- Conditions
- Hepatitis B Infection, Pregnant Women, Early Pregnancy
- Trial name
- TAF;CHB (NCT07668934)
- Testing
- TAF, TDF
- Where
- China
- Volunteers
- 816 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Aplastic Anemia
Efficacy and Safety of Avatrombopag Combined With IST for the Treatment of HAAA and SAA With Abnormal Liver Function
This is a multicenter, single-arm clinical study. The objective was to evaluate the efficacy and safety of Avatrombopag combined with IST in very/sever aplastic anemia patients with abnormal liver function or HAAA patients…
- Trial name
- NCT05571332
- Testing
- Avatrombopag 20 MG Oral Tablet
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hepatitis C
An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the efficacy of simeprevir in combination with sofosbuvir for 8 or 12 weeks versus a historical control, with respect to the percentage of participants with sustained virologic response at…
- Trial name
- NCT02278419
- Testing
- Simeprevir, Sofosbuvir
- Where
- 2 sites in Egypt
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Janssen-Cilag International NV
Alcoholic Hepatitis
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
The main purpose of this study is to test the effectiveness of Obeticholic Acid when used in patients with moderately severe alcoholic hepatitis.
- Trial name
- TREAT (NCT02039219)
- Testing
- 10 mg Obeticholic Acid (OCA)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Naga P. Chalasani
Chronic Hepatitis C
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.
- Trial name
- NCT00537407
- Testing
- Debio 025, Peg-IFNα2a, Ribavirin
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Debiopharm International SA
Hepatitis C
A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults
The purpose of this study is to evaluate the effect that telaprevir has on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacokinetics means how the drug is absorbed into the bloodstream, distributed in the body and…
- Trial name
- NCT01038167
- Testing
- telaprevir, cyclosporine, tacrolimus
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Chronic Hepatitis C
Efficacy of Paroxetine in the Prevention of Depressive Syndrome in Patients With Chronic Hepatitis C Treated by PEG-Interferon Alfa Plus Ribavirin
Depression is a common side effect of interferon in the treatment of chronic hepatitis C. The aim of this study is to assess the efficacy and safety of paroxetine, an antidepressant agent, in the prevention of depression induced…
- Trial name
- NCT00196664
- Testing
- Paroxetine
- Where
- France
- Volunteers
- 144 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Hepatitis C Viral Infection, Chronic Hepatitis C
A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection
Phase 2 study designed to assess the safety, efficacy, and pharmacokinetics of Faldaprevir and TD-6450 alone or in combination with other antivirals for a 12-week treatment duration in treatment-naïve participants with genotype…
- Conditions
- Hepatitis C Viral Infection, Chronic Hepatitis C, Hepatitis C (HCV), Hepatitis C Genotype 1
- Trial name
- NCT02716428
- Testing
- Faldaprevir, TD-6450, Ribavirin
- Where
- 6 sites in United States, New Zealand
- Volunteers
- 25 people
- Sponsor
- Trek Therapeutics, PBC
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
MASLD Butyrate Supplementation Treatment Efficacy Review
1. Study Design This is an interventional study designed to evaluate the efficacy of oral butyrate supplementation in patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD). 2.
- Trial name
- MASTER (NCT06759363)
- Testing
- Sodium-Butyrate, Calcium Butyrate
- Where
- Serbia
- Volunteers
- 200 people
- Sponsor
- University Medical Center Zvezdara
Chronic Hepatitis B
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
The purpose of this study is to examine the immunogenicity and efficacy of HBsAg Vaccine in combination with Entecavir in patients who have been treated with HB110E HBV DNA vaccine.
- Trial name
- NCT01813487
- Testing
- HBsAg vaccine with Entecavir
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Genexine, Inc.
Carcinoma, Hepatocellular
Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load
Antiviral therapy for HBV may play an important role here, as a large observation study from Taiwan reported that the use of nucleos(t)ide analogues (NUC) was associated with 33% reduction in HCC recurrence.
- Trial name
- POWER (NCT02308319)
- Testing
- Tenofovir disoproxil fumarate
- Volunteers
- 124 people
- Sponsor
- Samsung Medical Center
HEPATITIS C (HCV), Hepatitis B Virus (HBV)
Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%…
- Conditions
- HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC)
- Trial name
- Mondelta (NCT07038863)
- Testing
- Community screening for hepatitis B, C and delta in the Mongolian population living in France
- Where
- 11 sites in France
- Volunteers
- 2,000 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis E
Study of AT-587 in Healthy Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of AT-587 in healthy subjects
- Trial name
- NCT07728487
- Testing
- AT-587
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Hepatitis C Virus
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
The objectives of this study are to collect and assess data related to safety and effectiveness of Sovaldi treatment regimens, per the approved prescribing information for Sovaldi, in routine clinical practice and report results…
- Trial name
- NCT02907996
- Testing
- Sofosbuvir
- Where
- 72 sites in South Korea
- Volunteers
- 2,033 people
- Sponsor
- Gilead Sciences
Infant, Premature
Vitamin A Supplementation in Preterm Infants
Extremely low birth weight infants have decreased blood levels of Vitamin A. This Vitamin A deficiency may increase the risk of infections and chronic lung disease in these infants.
- Trial name
- NCT00063596
- Testing
- Vitamin A supplementation
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hepatitis B
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
The goals of therapy against chronic hepatitis B are to decrease the morbidity and mortality related to chronic HBV infection. Currently available antiviral therapy can suppress viral replication but only a small proportion…
- Trial name
- APOSTLE (NCT03312023)
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis B, Chronic
Dose-Ranging Study of Pradefovir in Patients With Compensated Hepatitis B
Compare the safety of four oral doses of pradefovir after 48 weeks of treatment Select the dose of pradefovir for Phase 3 studies
- Trial name
- NCT00230503
- Testing
- pradefovir mesylate, adefovir dipivoxyl
- Volunteers
- 220 people
- Sponsor
- Bausch Health Americas, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.